Pulmonx Corporation (LUNG)

In our clinic, evaluating minimally invasive interventions for lung disease requires keeping a close eye on pipeline maturation like the upcoming AeriSeal therapy launch targeted for late next year. While current procedures deal with commercial reorganization and sales force rebuilding in the U.S., watching how the technical adoption curves hold up internationally—outside of the China suspension headwinds—gives us a clearer baseline for procedural consistency and volume trajectory.

On our desk, the narrative shift around LUNG is all about execution risk meeting improved cost discipline. Even though analysts recently cut price targets to $3.40, the stock jumped 39% over the week following Q2 results because statutory losses narrowed 14% better than expected and gross margins hit an impressive 78%. Management is holding firm on a $90M to $92M full-year revenue guide while trimming operating expenses through cost restructuring.

Watching the 50-day moving average and volume behavior, the primary risk factors for LUNG center on top-line volatility. Worldwide revenue contracted 5% year-over-year in Q2 to $22.8 million strictly due to missing China shipments, and domestic sales fell 4% due to the ongoing sales force overhaul. Investors need to weigh whether the impressive margin gains and lower stock-based compensation can fully offset near-term revenue stagnation.